Trials / Completed
CompletedNCT00433615
Clinical Study of R744 to Predialysis Patients
Switch and Maintenance Study of Subcutaneous or Intravenous Injections of R744 to Predialysis Patients ( Phase Ⅲ Study ).
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 124 (actual)
- Sponsor
- Chugai Pharmaceutical · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy and safety of subcutaneous or intravenous R744 in renal anemia patients on Predialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | R744 | 100μg(s.c./i.v.)/4 week for 8 weeks, then 25\~400μg(s.c./i.v.)/4 week for 40 weeks |
| DRUG | R744 | 150μg(s.c./i.v.)/4 week for 8 weeks, then 25\~400μg(s.c./i.v.)/4 week for 40 weeks |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2007-02-12
- Last updated
- 2009-02-02
Locations
6 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00433615. Inclusion in this directory is not an endorsement.